PMID- 26380441
OWN - NLM
STAT- MEDLINE
DCOM- 20160915
LR  - 20181202
IS  - 1003-5370 (Print)
IS  - 1003-5370 (Linking)
VI  - 35
IP  - 7
DP  - 2015 Jul
TI  - [Treatment of Chronic Heart Failure Patients with Qi-Yang Deficiency and Blood 
      Stasis Resistance Syndrome by Xnmallong Injection: a Multi-center Randomized 
      Control Study].
PG  - 796-800
AB  - OBJECTIVE: To evaluate the efficacy and safety of Xinmailong Injection (XI) in 
      treatment of chronic heart failure (CHF) patients with qi-yang deficiency and 
      blood stasis resistance syndrome (QY-DBSRS). METHODS: Totally 238 CHF patients 
      with QYDBSRS were assigned to the treatment group (118 cases) and the control 
      group (120 cases) by randomized, double-blind, placebo parallel controlled 
      method. Patients in the treatment group received routine therapy and XI (100 mg/2 
      mL, by dripping at 5 mg/kg, twice per day for 5 consecutive days), while those in 
      the control group received routine therapy and XI mimetic agent (100 mg/2 mL, by 
      dripping at 5 mg/kg, twice per day for 5 consecutive days). The heart function 
      classification of New York Heart Association (NYHA), 6-min walking distance, left 
      ventricular ejection fraction (LVEF), scores for Chinese medical symptoms were 
      observed before and after treatment, and safety assessed. RESULTS: Totally 235 
      patients actually entered full analysis set (FAS), including 120 cases in the 
      control group and 115 cases in the treatment group. The total effective rate of 
      heart function, 6-min walking distance and increased post-pre-treatment distance 
      in the experimental group were superior to those of the control group with 
      statistical difference (all P < 0.05). Compared with the control group, increased 
      value of post-pre-treatment LVEF, the total effective rate of Chinese medical 
      syndrome efficacy, scores for Chinese medical symptoms and decreased 
      post-pre-treatment value of Chinese medical syndrome scores were obviously 
      improved (all P < 0.05). There was no significant difference in the incidence of 
      adverse events between the two groups (P > 0.05). CONCLUSIONS: XI could improve 
      the heart function of CHF patients, improve Chinese medical symptoms, elevate 
      exercise tolerance, and improve LVEF. It had no obvious toxic and side effects.
FAU - Xue, Jin-gui
AU  - Xue JG
FAU - Wang, Xiao-long
AU  - Wang XL
FAU - Xu, Yong
AU  - Xu Y
FAU - Li, Feng-chun
AU  - Li FC
FAU - Liu, Li
AU  - Liu L
FAU - Wang, Xing
AU  - Wang X
FAU - Wang, Jian-zhong
AU  - Wang JZ
FAU - Liu, Fan
AU  - Liu F
LA  - chi
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhongguo Zhong Xi Yi Jie He Za Zhi
JT  - Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese 
      journal of integrated traditional and Western medicine
JID - 9211576
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Chronic Disease
MH  - Double-Blind Method
MH  - Drugs, Chinese Herbal/administration & dosage/pharmacology/*therapeutic use
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Injections
MH  - Medicine, Chinese Traditional
MH  - Phytotherapy
MH  - *Qi
MH  - Syndrome
MH  - *Yang Deficiency
EDAT- 2015/09/19 06:00
MHDA- 2016/09/16 06:00
CRDT- 2015/09/19 06:00
PHST- 2015/09/19 06:00 [entrez]
PHST- 2015/09/19 06:00 [pubmed]
PHST- 2016/09/16 06:00 [medline]
PST - ppublish
SO  - Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015 Jul;35(7):796-800.